PTK7: an underestimated contributor to human cancer

Zhipeng Jin; Tianyu Guo; Xue Zhang; Xin Wang; Yefu Liu

doi:10.3389/fonc.2024.1448695

Frontiers in Oncology (Oct 2024)

PTK7: an underestimated contributor to human cancer

Zhipeng Jin,
Tianyu Guo,
Xue Zhang,
Xin Wang,
Yefu Liu

Affiliations

Zhipeng Jin: Department of Hepatopancreatobiliary Surgery, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Tianyu Guo: Department of Hepatopancreatobiliary Surgery, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Xue Zhang: Central Laboratory, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Xin Wang: Department of Hepatopancreatobiliary Surgery, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Yefu Liu: Department of Hepatopancreatobiliary Surgery, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

DOI: https://doi.org/10.3389/fonc.2024.1448695
Journal volume & issue: Vol. 14

Abstract

Read online

Protein tyrosine kinase 7 (PTK7) is an evolutionarily conserved transmembrane receptor and a specialized tyrosine kinase protein lacking kinase activity. PTK7 has been found to be strongly associated with a variety of diseases, including cancer. In this review, we will provide a comprehensive overview of the involvement of PTK7 in human cancer, focusing on the changing research landscape of PTK7 in cancer research, the molecular mechanisms of PTK7 involved in cancer progression, the targetability of PTK7 in cancer therapy, and the potential application of PTK7 in cancer management, thus demonstrating that PTK7 may be an underestimated contributor to human cancer.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords